Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours (Q35274974)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

0 references

author name string

A J Zurita

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

M Khajavi

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

H-K Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

L Tye

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

X Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

M H Kulke

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

H-J Lenz

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

N J Meropol

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

W Carley

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

S E DePrimo

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

E Lin

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

X Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

C S Harmon

13

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

J V Heymach

14

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

31 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

112

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1199-1205

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

1 March 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Interaction of tumor cells and lymphatic vessels in cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Molecular Predictors of Response to Antiangiogenesis Therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

12 July 2018

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4385961

26 September 2018

VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.73

21 January 2018

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.73

21 January 2018

Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia stimulates CXCR4 signalling in ileal carcinoids

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers and response to bevacizumab--letter

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2015.73

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35274974&oldid=2197393049"